<code id='3512DD6EFB'></code><style id='3512DD6EFB'></style>
    • <acronym id='3512DD6EFB'></acronym>
      <center id='3512DD6EFB'><center id='3512DD6EFB'><tfoot id='3512DD6EFB'></tfoot></center><abbr id='3512DD6EFB'><dir id='3512DD6EFB'><tfoot id='3512DD6EFB'></tfoot><noframes id='3512DD6EFB'>

    • <optgroup id='3512DD6EFB'><strike id='3512DD6EFB'><sup id='3512DD6EFB'></sup></strike><code id='3512DD6EFB'></code></optgroup>
        1. <b id='3512DD6EFB'><label id='3512DD6EFB'><select id='3512DD6EFB'><dt id='3512DD6EFB'><span id='3512DD6EFB'></span></dt></select></label></b><u id='3512DD6EFB'></u>
          <i id='3512DD6EFB'><strike id='3512DD6EFB'><tt id='3512DD6EFB'><pre id='3512DD6EFB'></pre></tt></strike></i>

          Home / explore / explore

          explore


          explore

          author:comprehensive    Page View:1791
          Adam's take main illustration
          Molly Ferguson/STAT

          Biotech is awash in PIPEs.

          The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.

          advertisement

          Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In